GLP-1 Market
LLY $1281.91 ▲ +0.2% NVO $38.67 ▼ -1.2% PFE $29.80 ▲ +0.0% VKTX $24.89 ▲ +2.8% KLRA $13.13 ▲ +2.8% GPCR $21.55 ▲ +2.1% RHHBY $60.37 ▲ +0.7%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

BMF-219

BMF-219

Company
Biomea Fusion Inc.
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
None currently listed

Efficacy results: Not yet reported

No recruiting studies currently listed

See all studies for this drug

Data source: ClinicalTrials.gov · trial data as of Oct 28, 2026

Trial details
  • Terminated NCT NCT05153330

    Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL

    Not yet reported Biomea Fusion Inc. 55 participants Est. completion 2025-05-02 41 sites Stand-alone
    Other conditions: Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Acute Mixed-Phenotype Leukemia, Cancer, Refractory, Progression, Diffuse Large B Cell Lymphoma, Multiple Myeloma, Lymphoma, Lymphoma, Non-Hodgkin, Myeloma, Plasma-Cell, Myelomatosis, Plasma Cell Myeloma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
    View official trial listing →
  • Terminated NCT NCT05631574

    Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer

    Not yet reported Biomea Fusion Inc. 13 participants Est. completion 2025-01-15 23 sites Stand-alone
    Other conditions: Non Small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer, NSCLC, PDAC, CRC, Relapsed Cancer, Refractory Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer, Stage III Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer, Stage III Colorectal Cancer, Stage IV Colorectal Cancer, Stage III NSCLC, Stage IV NSCLC, KRAS Mutation-Related Tumors
    View official trial listing →
  • Completed NCT NCT05731544

    Study of BMF-219 in Healthy Adult Subjects and in Adult Subjects With Type 2 Diabetes Mellitus (T2D)

    Not yet reported, Not yet reported Biomea Fusion Inc. 443 participants Est. completion 2025-07-08 39 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT06152042

    Phase 2 Trial of BMF-219 in Participants With Type 1 Diabetes Mellitus

    Not yet reported Biomea Fusion Inc. 37 participants Est. completion 2025-07-18 11 sites Stand-alone
    Other conditions: Type 1 Diabetes Mellitus
    View official trial listing →
  • Completed NCT NCT07254286

    Food Effect Study in Healthy Volunteers

    Not yet reported Biomea Fusion Inc. 60 participants Est. completion 2026-01-14 1 site
    Other conditions: Healthy Volunteer
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.